Chemical Classification and Structure
To understand the properties of local anesthetics, they are traditionally divided into two main groups based on the type of chemical bond connecting the aromatic ring to the amino group.
Tetracaine belongs to the ester group, containing an ester linkage. This group also includes well-known agents such as procaine hydrochloride (novocaine) and benzocaine. By contrast, the second major group—substituted acid amides (containing an amide linkage)—includes lidocaine, bupivacaine, and articaine (the latter also containing a thiophene ring).
Chemically, tetracaine is the 2-dimethylaminoethyl ester of p-butylaminobenzoic acid. In medical practice, it is used as the hydrochloride salt, which possesses an important physicochemical property: it is readily soluble in water and alcohol, facilitating the preparation of anesthetic solutions.
Pharmacological Profile and Toxicity
When evaluating its pharmacological profile, tetracaine is frequently compared to cocaine. The drug exhibits an exceptionally strong local anesthetic effect, with potency approximately 10 times that of cocaine. However, this high efficacy is accompanied by severe risks.
The toxicity of tetracaine is 2 to 5 times greater than that of cocaine. The primary danger lies in its pharmacokinetic properties: tetracaine has an extremely high capacity for absorption through mucous membranes into the systemic circulation. This creates a high risk of resorptive systemic toxicity.
The clinical presentation of severe tetracaine poisoning develops in stages:
- Phase 1: Marked central nervous system (CNS) excitation.
- Phase 2: Profound CNS depression.
- Severe Intoxication: Can lead to fatal outcomes secondary to respiratory center paralysis.
Ophthalmological Applications
Despite limitations, tetracaine is widely used in ophthalmology due to its rapid onset of action (pronounced anesthesia develops within 1–2 minutes). The drug has significant advantages over cocaine: it has virtually no effect on intraocular pressure and does not cause mydriasis (pupil dilation).
Solution concentration is strictly determined by the intended procedure:
- 0.1% solution: Used for routine intraocular pressure measurement (tonometry).
- 0.25–1% or 2% solutions: Used for foreign body removal and various intraocular surgeries.
- 0.5% solution: Considered the standard concentration for most surgical interventions.
Important Limitations: Solutions with concentrations exceeding 2% are strongly discouraged because they can damage the corneal epithelium. Additionally, the drug can cause significant conjunctival vasodilation. When prolonged ocular anesthesia is required, specialized ocular inserts containing a strictly controlled dose of tetracaine (0.75 mg) are used instead of drops.
ENT Practice and the Role of Vasoconstrictors
In addition to ophthalmology, tetracaine is used for topical anesthesia of the nasal and nasopharyngeal mucosa. For these purposes, solutions ranging from 1% to 2% are typically utilized.
To minimize the substantial risk of systemic toxicity associated with rapid mucosal absorption, a specific pharmacological strategy is employed: vasoconstrictors, notably epinephrine (adrenaline), are added to tetracaine solutions.
This combination serves several purposes:
- Sharply decreases the systemic absorption of anesthetic molecules.
- Significantly reduces the overall toxic load on the patient's body.
- Prolongs the duration of action and enhances the local analgesic effect by retaining the drug within the local tissues.